Comparative Pharmacology
Head-to-head clinical analysis: INTEGRILIN versus TICLID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INTEGRILIN versus TICLID.
INTEGRILIN vs TICLID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible antagonist of the platelet glycoprotein IIb/IIIa receptor, inhibiting platelet aggregation by preventing fibrinogen binding.
Ticlopidine is a thienopyridine ADP receptor antagonist that irreversibly inhibits the P2Y12 receptor on platelets, preventing ADP-induced platelet aggregation.
Acute coronary syndrome: IV bolus of 180 mcg/kg, followed by continuous IV infusion of 2 mcg/kg/min for up to 72 hours. Percutaneous coronary intervention: IV bolus of 180 mcg/kg immediately before PCI, followed by continuous IV infusion of 2 mcg/kg/min for up to 18-24 hours, with a second 180 mcg/kg bolus 10 minutes after the first.
250 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life: ~2.5 hours (2-3 hours) after intravenous administration; clinical context: rapid clearance allows return of platelet function within 4 hours after infusion cessation.
Terminal elimination half-life is approximately 30-50 hours (mean ~33 hours), with clinical effects lasting 7-10 days after discontinuation due to irreversible platelet binding.
Renal: ~50% as unchanged drug and metabolites, Biliary/fecal: minimal; total clearance approximately 55-58% renal.
Primarily hepatic metabolism; 60% renal as metabolites, 23% fecal. Minimal parent drug excreted unchanged.
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent